Menopause
Drug research and approvals for menopause: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 178 studies of menopause are recruiting on ClinicalTrials.gov, Health Canada has authorized 6 drug trials for it since 2013, and the EU has 2 authorised medicines for it.
- Recruiting worldwide: 178
- Trials authorized in Canada: 6
- FDA orphan approvals: 0
- EU medicines: 2
Recruiting Now
Newest start dates first, of 178 recruiting on ClinicalTrials.gov ↗- Effects of a Dietary Supplement in Women With Late Perimenopause or Early PostmenopauseNCT07863973 · Not applicable · University of Alicante · starts Nov 1, 2026
- Time-Restricted Eating and Personalized Energy-Restricted Diet in Obese Postmenopausal WomenNCT07874399 · Not applicable · Gazi University · starts Nov 1, 2026
- Haelan 951 for Menopause Symptoms in Peri- and Postmenopausal WomenNCT07751029 · Not applicable · Spectrum Clinical Research, LLC · starts Oct 26, 2026
- Hop Extract Versus Soy Isoflavone Extract for Menopausal Symptoms (HOPES)NCT07904390 · Not applicable · Menoclinica by Palacios · starts Oct 26, 2026
- A Study to Confirm if Fezolinetant Helps to Reduce Hot Flashes in Indian Women Going Through MenopauseNCT07829653 · Phase 3 · Astellas Pharma Inc · starts Oct 23, 2026
- Effect of Lifestyle Intervention on Menopausal Symptoms, Sleep Quality, and Anxiety in Peri- and Postmenopausal WomenNCT07860645 · Not applicable · Konya Beyhekim Training and Research Hospital · starts Oct 15, 2026
- MenoZen VR for Menopause Symptom ManagementNCT07633743 · Not applicable · Mayo Clinic · starts Sep 28, 2026
- Dairy Choline BioavailabilityNCT06902480 · Not applicable · University of Wisconsin, Madison · starts Sep 18, 2026
- Heart Failure in Women: Epidemiological and Prognostic InsightsNCT07847983 · Not reported · Carolina Ortiz Cortes · starts Sep 17, 2026
- Brazilian Registry of Menopausal HealthNCT07005648 · Not reported · Science Valley Research Institute · starts Sep 11, 2026
Drug Pipeline
9 approved, 20 in phase 3, 11 in phase 2, 9 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Estrogens, conjugated, Estrogens, esterified, Estradiol valerate, Paroxetine, Synthetic conjugated estrogens, b, Estradiol acetate, Estrogens, conjugated synthetic a, Estrone sulfuric acid, Ospemifene
- Progesterone
- Phase 3 Progesterone receptor agonist
- Bazedoxifene
- Phase 3 Estrogen receptor modulator
- Medroxyprogesterone acetate
- Phase 3 Progesterone receptor agonist
- Isoflavone
- Phase 3
- Desvenlafaxine
- Phase 3 Serotonin transporter inhibitor
- Dydrogesterone
- Phase 3 Progesterone receptor agonist
- Elinzanetant
- Phase 3 Neurokinin 1 receptor antagonist
- Ethisterone
- Phase 3
- Testosterone
- Phase 3 Androgen Receptor agonist
- Tibolone
- Phase 3
- Tamoxifen
- Phase 3 Estrogen receptor alpha modulator
- Norethindrone acetate
- Phase 3 Progesterone receptor agonist
- Prasterone
- Phase 3 Unknown
- Calcitonin salmon
- Phase 3 Calcitonin receptor agonist
- Goserelin
- Phase 3 Gonadotropin-releasing hormone receptor agonist
- Ergocalciferol
- Phase 3 Vitamin D receptor agonist
- Letrozole
- Phase 3 Cytochrome P450 19A1 inhibitor
- Cyclophosphamide anhydrous
- Phase 3 DNA inhibitor
- Ascorbic acid
- Phase 3 Supplement
- Vitamin e
- Phase 3
- Methyltestosterone
- Phase 2 Androgen Receptor agonist
- Estriol
- Phase 2 Estrogen receptor modulator
- Withanolide d
- Phase 2
- Raloxifene
- Phase 2 Estrogen receptor beta modulator
- Risedronic acid
- Phase 2 Farnesyl diphosphate synthase inhibitor
- AUS-131
- Phase 2 Estrogen receptor beta agonist
- MF101
- Phase 2 Estrogen receptor beta agonist
- Asoprisnil
- Phase 2 Progesterone receptor modulator
- SMC021
- Phase 2 Calcitonin receptor agonist
- Melatonin
- Phase 2 Melatonin receptor agonist
Showing the 30 furthest along of 40 in trials.
Trials Authorized in Canada
Newest first; search them all in Canada trials| Jul 28, 2021 | A phase 3b, randomized, double-blind, placebo-controlled, 24-week study to assess the efficacy and safety of fezolinetant in menopausal women suffering from…Fezolinetant (ESN364) | Astellas Pharma | Closed |
| Sep 30, 2020 | A randomized double-blind placebo controlled phase 3 trial to evaluate the efficacy and safety of estetrol for the treatment of moderate to severe vasomotor…estetrol/ progesterone | Estetra Srl | Closed |
| Sep 27, 2019 | A randomized double-blind placebo controlled phase 3 trial to evaluate the efficacy and safety of estetrol for the treatment of moderate to severe vasomotor…Estetrol | Estetra Sprl | Closed |
| Jul 5, 2019 | A phase 3, randomized, placebo-controlled, 12-week double-blind study, followed by a non-controlled extension treatment period, to assess the efficacy and…Fezolinetant | Astellas Pharma | Closed |
| Jul 5, 2019 | A phase 3 randomized, placebo-controlled, 12-week double-blind study, followed by a non-controlled extension treatment period, to assess the efficacy and…Fezolinetant | Astellas Pharma | Closed |
| Apr 25, 2019 | A randomized, placebo-controlled, double-blind phase 3 clinical study to investigate the long-term safety of fezolinetant in women suffering from vasomotor…Fezolinetant | Astellas Pharma | Closed |
Medicines Authorised in the EU
Newest first| Mar 26, 2026 | FylrevyEstetrol | Gedeon Richter Plc. | EMA ↗ |
| Dec 7, 2023 | VeozaFezolinetant | Astellas Pharma Europe B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA